Percutaneous Transvenous Coil Embolization Treatment for Liver Shunts

Update: This procedure is now available at several locations around the country.

Last year, we published a post on a promising new procedure, Percutaneous Transvenous Coil Embolization (PTCE) for the repair of liver shunts. The first scientific paper has come out on this procedure, but Dr. Cassie Lux, Assistant Professor of Surgery at the College of Veterinary Medicine at the University of Tennessee, very generously wrote up for us how the procedure works: Read more

Promising New Procedure for Liver (Portosystemic) Shunts

Update: This procedure is now available at several locations around the country, and we have published additional information on it here and here.

Some promising news regarding correcting portosystemic shunts in dogs comes from U.C. Davis, where Dr. Bill Culp has developed a new, non-invasive way to close intrahepatic shunts, which historically have been difficult to correct surgically.

Read more

Announcement from the University of Pennsylvania for a clinical trial for hemangiosarcoma:

Further Evaluation of the Benefits of a Traditional Chinese Medicine Supplement for Dogs with Splenic Hemangiosarcoma

Dec 6, 2013
In a previous study conducted here at PennVet, the mushroom supplement I’m-Yunity® significantly increased survival time in dogs with splenic hemangiosarcoma. I’m-Yunity® extract effectively delivers the standardized ingredient polysaccharopeptide (PSP) which can only be isolated from the Coriolus Versicolor mushroom.

In this new trial, we will be comparing I’m-Yunity’s® effect on survival time and quality of life to the standard chemotherapy treatment.

Dogs will randomly be chosen to receive either chemotherapy, I’m-Yunity® treatment, or both concurrently, and owners will not know to which treatment group their dog was assigned. Dogs enrolled in this study will have 11 weekly visits, followed by monthly follow-up visits until the end of their life.

Eligibility:

  • Diagnosis of hemangiosarcoma following splenectomy.
  • At least 4 kg.
  • Not currently undergoing treatment for cancer.
  • No other significant health concerns that are an immediate threat to life.
  • Ability to administer oral medication (pills) to your dog.

Please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu for more information about this study.

Chinese Medicine Holdings, the makers of I’m-Yunity supplement, is the sponsor of both studies,  but both studies were designed by the Penn clinical epidemiologist, who is also the principle investigator.